News
Novel Vaccine Shows Promise in Pancreatic Cancer
An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive survival outcomes in patients with resected pancreatic and colorectal cancers, according to final results from the phase I AMPLIFY-201 trial.
New vaccine designed to help fight colorectal, pancreatic cancer shows promising results: Study
A new vaccine designed to combat cancer cells in patients with colorectal and pancreatic cancer showed promising results in its phase 1 trial. Researchers at the University of California said 21 out of 25 patients generated an immune response to cancer cells.
The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune ...
Federal funding cuts to mRNA technology research doesn't just impact COVID vaccines — experts say it could stall progress in treatment for cancers, rare disease and more.
IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...
New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.
Best Life on MSN1d
Colon Cancer Vaccine Gets One Step Closer to Reality
The "off-the-shelf" vaccine has also shown promising results for pancreatic cancer. Since the U.S. Preventive Services Task ...
IDSA emphasized that the VICP be funded appropriately to compensate injured individuals without putting an infeasible burden ...
IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late ...
Scientists have discovered the ability to “personalize” cancer treatments using cutting-edge genetic technology - but experts ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback